NASDAQ:STTK Shattuck Labs Q4 2025 Earnings Report $7.42 +0.10 (+1.37%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$7.49 +0.07 (+0.94%) As of 08/14/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Shattuck Labs EPS ResultsActual EPS-$0.12Consensus EPS -$0.12Beat/MissMet ExpectationsOne Year Ago EPSN/AShattuck Labs Revenue ResultsActual Revenue($1.00) millionExpected Revenue$0.17 millionBeat/MissMissed by -$1.17 millionYoY Revenue GrowthN/AShattuck Labs Announcement DetailsQuarterQ4 2025Date3/5/2026TimeBefore Market OpensConference Call DateThursday, March 5, 2026Conference Call Time6:30AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Shattuck Labs Earnings HeadlinesShattuck Labs (NASDAQ:STTK) Rating Lowered to Hold at Wall Street ZenAugust 15 at 2:13 AM | americanbankingnews.comHC Wainwright Increases Earnings Estimates for Shattuck LabsAugust 15 at 1:29 AM | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.August 15 at 1:00 AM | InvestorPlace (Ad)HC Wainwright Issues Pessimistic Forecast for Shattuck Labs (NASDAQ:STTK) Stock PriceAugust 13 at 2:01 AM | americanbankingnews.comShattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value MilestoneAugust 12 at 12:50 PM | tipranks.comShattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 11, 2026 | markets.businessinsider.comSee More Shattuck Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email. Email Address About Shattuck LabsShattuck Labs (NASDAQ:STTK) (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier. The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities. Preclinical studies have demonstrated that vaccinated animals produce robust anti‐fentanyl antibody titers and are protected against lethal and sublethal fentanyl challenges. Shattuck Labs is advancing its vaccine candidate through IND‐enabling studies and plans to initiate first‐in‐human trials to evaluate safety, immunogenicity, and its potential to block the psychoactive effects of fentanyl. Founded in 2017, Shattuck Labs was established to address the growing public health crisis posed by opioid misuse and overdose. The company leverages insights from immunology and vaccinology, collaborating with academic partners and contract manufacturing organizations to streamline development and scale up production. Shattuck Labs serves the U.S. market and is preparing for broader geographic reach as its clinical programs progress. Shattuck Labs is led by Chief Executive Officer Craig H. Wheeler, who brings extensive experience in biopharmaceutical R&D and commercial strategy. The management team includes experts in vaccine formulation, regulatory affairs, and translational medicine. Through its focused pipeline and innovative platform, Shattuck Labs aims to pioneer a new class of non‐addictive, immunotherapeutic treatments for substance use disorders.View Shattuck Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneCerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More Divided Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
